VanEck Associates
AGL icon

VanEck Associates’s Agilon Health AGL Stock Holding History

VanEck Associates’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41
Closed -$3K – 1388
2024
Q3 		$3K Sell
41
-28
-41% -$3.62K ﹤0.01% 1363
2024
Q2 		$11K Buy
69
+32
+86% +$4.56K ﹤0.01% 1340
2024
Q1 		$6K Sell
37
-32
-46% -$5.32K ﹤0.01% 1341
2023
Q4 		$22K Sell
69
-95
-58% -$34.4K ﹤0.01% 1330
2023
Q3 		$73K Buy
164
+102
+165% +$46.1K ﹤0.01% 1255
2023
Q2 		$27K Sell
62
-5
-7% -$2.81K ﹤0.01% 1339
2023
Q1 		$40K Sell
67
-43
-39% -$24.1K ﹤0.01% 1315
2022
Q4 		$44K Buy
110
+33
+43% +$15.5K ﹤0.01% 1321
2022
Q3 		$45K Buy
+77
New +$46.1K ﹤0.01% 1270

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VanEck Associates's AGL Position: Q4 2024 in Review

VanEck Associates sold out of Agilon Health (AGL) in Q4 2024, closing a stake of 41 shares — an estimated $3K sold.

VanEck Associates first reported a position in AGL in Q3 2022 and held it in 9 quarters. The position peaked at $73K in Q3 2023. 184 funds tracked by Wall St. Rank hold AGL as of Q4 2024.

  • VanEck Associates reported no remaining Agilon Health position as of Q4 2024 after selling out during the quarter.
  • VanEck Associates sold 41 Agilon Health shares in Q4 2024, an estimated $3K.
  • VanEck Associates first reported a position in Agilon Health in Q3 2022 and held it in 9 quarters.
  • VanEck Associates's Agilon Health position peaked at $73K in Q3 2023.
  • 184 funds tracked by Wall St. Rank held Agilon Health as of Q4 2024.

Based on VanEck Associates's 13F filing for Q4 2024, filed 29 Jan 2025.